Journal of Isfahan Medical School

Journal of Isfahan Medical School

Roadmap for Controlling the Indigenous Threat of Anthrax

Document Type : policy brief

Authors
1 Department of Infectious Disease Prevention and Control, Provincial Health Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Nutrition and Food Security Research Center, Department of Health Education and Health Promotion, Isfahan University of Medical Sciences, Isfahan, Iran
3 Faculty of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran
4 Vice President of University Health, Head of Provincial Health Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
This analytical document examines the epidemiological trends of Anthrax in Isfahan Province over a decade (2011–2021) based on data collected from authoritative sources. The primary findings indicate a distinct geographical pattern of the disease, with a major concentration in the western and southwestern regions of the province, and a significant correlation with livestock-related occupational activities. The seasonal peak of incidence was observed during the spring and summer months, along with a relative increase in cases between 2013 and 2017. Based on this evidence, five key policy options for the control and prevention of Anthrax were identified and analyzed: 1) Strengthening livestock vaccination in high-risk areas, 2) Establishing a seasonal surveillance and monitoring system prior to high-risk periods, 3) Education and empowerment of livestock farmers and agriculturists, 4) Increasing supervision over livestock entry and movement, and 5) Launching mobile laboratories in rural areas. The prioritization of these options—based on their impact on the disease transmission cycle, feasibility regarding provincial capacities, and expert consensus is as follows: Strengthening livestock vaccination was identified as the first priority due to its maximum impact on disease reduction. Subsequently, seasonal surveillance systems (due to their essential role in early detection and rapid response) and community education (as a complement to ensure the sustained effectiveness of other interventions) are placed in the next priorities. Options regarding livestock movement supervision and the development of mobile laboratories are proposed as supportive and long-term measures.

Highlights

Abolfazl Hajari: Google Scholar

Sahebjan Torkian: Google Scholar

Reza Fadaei Nobari : Google Scholar

Mehrdad Zeinalian : Google Scholar

Hamid Galehdari : Google Scholar

Keywords
Subjects

1.     Saedi Z, Govanji Sh. Mohebatkar H. Effect of inhibitor for black venom receptor on human cells using bioinformatics tools [in Persian]. Biol J Tarbiat Modares Univ 2017; 8(1): 77-96.
2.     Zubair M. A review on laboratory investigation of anthrax as causative infectious disease and future perspectives. Sch Bull 2021; 7(7): 190-5.
3.     Hajari A, Fadaei Nobari R, Ghasemi AA, Ahmadi H, Abbaspour R, Zeinilian M. Investigation of the epidemiology of anthrax in Isfahan province during the years 2011 to 2022. Proceedings of the 1st International Conference on Health, Hygiene and Education; Sari, Iran; 2024. [in Persian].
4.     Stears K, Schmitt MH, Turner WC, McCauley DJ, Muse EA, Kiwango H, et al. Hippopotamus movements structure the spatiotemporal dynamics of an active anthrax outbreak. Ecosphere 2021; 12(6): e03540
5.     Ramezanpoor J, Abaspoor Najafabadi R, Hajari A, Fadaei Nobari R. An epidemiologic study of human anthrax in counties under the supervision of Isfahan University of Medical Sciences during 2012-2015 [in Persian]. MCS 2017; 4(3): 178-86.
6.     Firstova VV, Shakhova AS, Riabko AK, Silkina MV, Zeninskaya NA, Romanenko YO, et al. Characterization of the adaptive immune response of donors receiving live anthrax vaccine. PloS One 2021; 16(12): e0260202.
7.     Abdous M, Hasannia S, Salmanian AH, Arab S-S. Efficacy assessment of a triple anthrax chimeric antigen as a vaccine candidate in guinea pigs: challenge test with Bacillus anthracis 17 JB strain spores. Immunopharmacol Immunotoxicol 2021; 43(4): 495-502.
 
Volume 44, Issue 871
3rd Week,September (Policy Brief)
September and October 2026
Pages 1317-1321

  • Receive Date 16 April 2026
  • Accept Date 20 April 2026